23andMe Q1 FY25 revenue down 34% to $40M; net loss improves to $69M; ends Therapeutics Discovery

Chrome Holding Co.

2026-Q1 EPS reported -$2.80 revenue$40,414,000

Revenue $40M, down 34% YoY due to lower research revenue after GSK exclusivity end and lower PGS kits/telehealth.
Net loss $69M vs $105M; adjusted EBITDA loss $35M vs $50M.
Cash $170M, down from $216M in prior quarter.
Ceasing Therapeutics Discovery operations effective Aug 9; terminating 30 employees.
Officer Bill Richards resigns effective Aug 23; severance includes $253.5K lump sum, COBRA, RSU acceleration of 90,265 RSUs.

item 2.02 item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Bill Richards

Head of Therapeutics Discovery

Chrome Holding Co.

Effective: 2024-08-23
Filed: August 8, 2024, 7:59 PM ET

On August 5, 2024, Bill Richards, the Head of Therapeutics Discovery, and a named executive officer of the Company, tendered his resignation to the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Bill Richards resigned as Head of Therapeutics Discovery at Chrome Holding Co..

Action: resigned
Role: Head of Therapeutics Discovery

Exact text from the filing

On August 5, 2024, Bill Richards, the Head of Therapeutics Discovery, and a named executive officer of the Company, tendered his resignation to the Company.

View on SEC.gov

Source: SEC EDGAR

accession 0001804591-24-000045

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.